Vaccine and Emerging Infections Research, Human Health Therapeutics Research Centre, National Research Council, Ottawa, ON K1A 0R6, Canada.
Can J Microbiol. 2020 Sep;66(9):529-534. doi: 10.1139/cjm-2020-0117. Epub 2020 May 12.
is becoming increasingly recognised as an emerging pathogen, gaining attention as a potential factor for exacerbating colorectal cancer and is strongly linked with pregnancy complications including pre-term and still births. Little is known about the virulence factors of this organism; thus, we have initiated studies to examine the bacterium's surface glycochemistry. In an effort to characterise the surface carbohydrates of , the aims of this study were to investigate the structure of the lipopolysaccharide (LPS) O-antigen of the cancer-associated isolate strain CC 7/3 JVN3 C1 (hereafter C1) and to develop monoclonal antibodies (mAbs) to the LPS O-antigen that may be beneficial to the growing field of research. In this study, we combined several technologies, including nuclear magnetic resonance (NMR) spectroscopy, to elucidate the structure of the LPS O-antigen repeat unit as -[-4-β-Gal-3-α-FucNAc4N-4-α-NeuNAc-]-. We have previously identified this structure as the LPS O-antigen repeat unit from strain 10953. In this present study, we developed a mAb to the C1 LPS O-antigen and confirmed the mAbs cross-reactivity to the 10953 strain, thus confirming the structural identity.
它（幽门螺杆菌）正日益被视为一种新兴病原体，作为加重结直肠癌的潜在因素而受到关注，并且与包括早产和死产在内的妊娠并发症密切相关。目前人们对这种生物体的毒力因子知之甚少；因此，我们已经开始研究以检查该细菌的表面糖化学。为了确定幽门螺杆菌的表面碳水化合物，本研究的目的是研究与癌症相关的分离株 CC7/3 JVN3 C1（以下简称 C1）的脂多糖（LPS）O-抗原的结构，并开发针对 LPS O-抗原的单克隆抗体（mAbs），这可能有益于日益发展的幽门螺杆菌研究领域。在这项研究中，我们结合了几种技术，包括核磁共振（NMR）光谱学，以阐明 LPS O-抗原重复单元的结构为 -[-4-β-Gal-3-α-FucNAc4N-4-α-NeuNAc-]-. 我们之前已经从菌株 10953 中鉴定出这种结构作为 LPS O-抗原重复单元。在本研究中，我们开发了针对 C1 LPS O-抗原的 mAb，并证实了 mAb 与 10953 菌株的交叉反应性，从而证实了结构的同一性。
